177 Lu-PSMA-617 RLT in mCRPC: A single center experience, the earlier could be the better.

Ozlem Nuray Sever,Umut Elboga,Ertan Sahin,Yusuf Burak Cayirli,Havva Yesil Cinkir

Revista espanola de medicina nuclear e imagen molecular（2023）

引用 0|浏览2

暂无评分

摘要

Lu-PSMA-617 RLT treatment provides better survival in the treatment of patients diagnosed with mCRPC after standard treatments and received it earlier. Lu-PSMA-617 RLT treatment could be an effective treatment method in mCRPC patients with bone and lymph node metastasis.

查看译文

关键词

Cáncer de próstata,Overall survival,Prostate cancer,Radioligand therapy,Supervivencia global,Terapia con radioligandos

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要